Skip to main content
. 2023 Jan 10;12(1):163. doi: 10.3390/antiox12010163

Figure A2.

Figure A2

Schematic workflow of the preliminary formulation study, which enabled the selection of the optimal lyoprotectant formula for all of the assays of the main study. Placebo samples contained no cellular derivatives. LYO-PLA, lyophilized placebo sample; LYO-LYS, lyophilized lysate fraction; LYO-MEM, lyophilized membrane fraction; LYO-SN, lyophilized soluble fraction; LYO-WC, lyophilized whole-cell fraction.